Vedanta Biosciences, Inc.

For patients in the US with recurrent Clostridioides difficile infection (rCDI), the recent approval of two safe and effective treatments is a win. Now the question for Seres Therapeutics, Inc. an

Venture capital fundraising by biopharmaceutical companies has been a mixed bag so far in 2023, with a slow start to the year but a relative surge in big financings in March and April. There were only

Clostridioides difficile infection (CDI) is a billion-dollar problem that microbiome-targeted companies are keen to solve. CDI is arguably the lowest-hanging fruit for microbiome-focused companies as

A mere four days after announcing a potential link-up, troubled US group Nektar Therapeutics and UK healthcare holding company PureTech have called off merger talks which had taken seasoned observers